Nidhi P. Goyal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nidhi P. Goyal has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey B. Schwimmer
Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics University of California San Diego School of Medicine La Jolla California USA
3 shared publications - Kimberly P. Newton
Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, California, USA
3 shared publications - Nhat Quang N. Thai
Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, California, USA
2 shared publications Andrew Wang
Division of Gastroenterology, Department of Pediatrics, Hepatology, and Nutrition, University of California San Diego School of Medicine, La Jolla, California, USA
1 shared publicationBonnie Lin
Division of Gastroenterology, Department of Pediatrics, Hepatology, and Nutrition, University of California San Diego School of Medicine, La Jolla, California, USA
1 shared publication- Cynthia A. Behling
Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University of California San Diego School of Medicine, La Jolla, California, USA
1 shared publication
Latest Publications
- 12 January 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 84 (1) , E9-E10
Reply: The PNPLA3 paradox—Does genotype modify the clinical utility of the MASLD framework in children?
- 12 January 2026
- Published by Wolters Kluwer Health in Hepatology
- Vol. 84 (1) , E9-E10
Reply: The PNPLA3 paradox—Does genotype modify the clinical utility of the MASLD framework in children?
- 4 August 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (3) , E98-E99
Reply: Blood pressure adjustment and competing risks analysis should be reconsidered in the mortality exploration among children with MASLD
- 4 August 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (3) , E98-E99
Reply: Blood pressure adjustment and competing risks analysis should be reconsidered in the mortality exploration among children with MASLD
- Top Cited Papers
- 22 April 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (3) , 561-574
Long-term mortality and extrahepatic outcomes in 1096 children with MASLD: A retrospective cohort study
Background & Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease in children, but its long-term outcomes are poorly understood. This study aimed to quantify mortality rates, identify causes of death, and evaluate the incidence of cirrhosis and extrahepatic outcomes in children with pediatric-onset MASLD. Approach & Results: The Longitudinal InVestigation Evaluating Results of Steatosis (LIVERS) study is a single-center, retrospective cohort study conducted at Rady Children’s Hospital San Diego. We included 1,096 children aged 2–18 years who were diagnosed with MASLD between 2000 and 2017 and followed for a mean of 8.5 years. Mortality was ascertained via the National Death Index, and comorbidities were assessed through follow-up research visits and medical records. Overall, 3.4% of children died, yielding a mortality rate of 398 per 100,000 person-years; nearly half of these deaths were liver-related. Male sex and lower high-density lipoprotein levels independently predicted increased mortality risk. The cumulative incidence of cirrhosis was 4.7%. High incidence rates of extrahepatic comorbidities were observed, including dyslipidemia (3,664 per 100,000 person-years), hypertension (1,901), obstructive sleep apnea (1,185), and type 2 diabetes (911). Conclusions: Pediatric MASLD is associated with significant premature mortality and a substantial burden of hepatic and extrahepatic comorbidities. These findings highlight the need for timely screening, early intervention, and long-term management strategies to improve outcomes for children with MASLD. Export
- 22 April 2025
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (3) , 561-574
Top Cited PapersLong-term mortality and extrahepatic outcomes in 1096 children with MASLD: A retrospective cohort study
Background & Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease in children, but its long-term outcomes are poorly understood. This study aimed to quantify mortality rates, identify causes of death, and evaluate the incidence of cirrhosis and extrahepatic outcomes in children with pediatric-onset MASLD. Approach & Results: The Longitudinal InVestigation Evaluating Results of Steatosis (LIVERS) study is a single-center, retrospective cohort study conducted at Rady Children’s Hospital San Diego. We included 1,096 children aged 2–18 years who were diagnosed with MASLD between 2000 and 2017 and followed for a mean of 8.5 years. Mortality was ascertained via the National Death Index, and comorbidities were assessed through follow-up research visits and medical records. Overall, 3.4% of children died, yielding a mortality rate of 398 per 100,000 person-years; nearly half of these deaths were liver-related. Male sex and lower high-density lipoprotein levels independently predicted increased mortality risk. The cumulative incidence of cirrhosis was 4.7%. High incidence rates of extrahepatic comorbidities were observed, including dyslipidemia (3,664 per 100,000 person-years), hypertension (1,901), obstructive sleep apnea (1,185), and type 2 diabetes (911). Conclusions: Pediatric MASLD is associated with significant premature mortality and a substantial burden of hepatic and extrahepatic comorbidities. These findings highlight the need for timely screening, early intervention, and long-term management strategies to improve outcomes for children with MASLD. Export